vidarabine has been researched along with Chromosome Deletion in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 17 (58.62) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S | 1 |
| Chevassut, T; Milne, K; Sturrock, B | 1 |
| Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Jain, N | 1 |
| Aloyz, R; Assouline, SE; Autexier, C; Chu, TW; Gryaznov, SM; Johnston, JB; Lees-Miller, SP; Martinez-Marignac, V; Shawi, M; Yu, Y | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Hallek, M | 1 |
| Bulian, P; Cerri, M; Chiarenza, A; Cortelezzi, A; Coscia, M; Cuneo, A; De Paoli, L; Del Giudice, I; Del Poeta, G; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Gentile, M; Ghilardi, G; Laurenti, L; Marasca, R; Massaia, M; Mauro, FR; Montillo, M; Morabito, F; Moreno, C; Motta, M; Neri, A; Perbellini, O; Rigolin, GM; Rossi, D; Tedeschi, A; Terzi-di-Bergamo, L; Vincelli, I; Visco, C; Zaja, F; Zinzani, PL | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P | 1 |
| Bühler, A; Busch, R; Denzel, T; Döhner, H; Groner, S; Häbe, S; Hallek, M; Mertens, D; Mohr, J; Sarno, A; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Stilgenbauer, S; Zenz, T | 1 |
| Bazargan, A; Tam, CS | 1 |
| Bergmann, M; Bühler, A; Busch, R; Denzel, T; Döhner, H; Edelmann, J; Eichhorst, B; Häbe, S; Hallek, M; Hensel, M; Hopfinger, G; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Hillmen, P | 1 |
| Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
| Döhner, H; Gribben, JG; Hallek, M; Keating, MJ; Stilgenbauer, S; Zenz, T | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L | 1 |
| De Braekeleer, M; Herry, A; Le Bris, MJ; Morel, F; Morice, P | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Algüneş, C; Demir, M; Ongören, S; Pala, FS; Pamuk, GE; Soysal, T; Tabakcioğlu, K; Turgut, B; Vural, O | 1 |
| Austen, B; Baker, C; Dyer, M; Gardiner, A; Majid, A; Moss, PA; Oscier, D; Powell, JE; Siebert, R; Skowronska, A; Stankovic, T; Taylor, AM | 1 |
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Bethge, W; Bokemeyer, C; Bornhäuser, M; Dierlamm, J; Gutierrez, NC; Hansen, T; Kröger, N; Liebisch, P; Miguel, JS; Nagler, A; Otterstetter, S; Penas, EM; Pérez-Simón, JA; San Miguel, J; Schilling, G; Schwerdtfeger, R; Shimoni, A; Simon-Perez, JA; Zabelina, T; Zander, A | 1 |
| Bryant, PE; Mozdarani, H | 1 |
| Huang, P; Plunkett, W; Siciliano, MJ | 1 |
5 review(s) available for vidarabine and Chromosome Deletion
| Article | Year |
|---|---|
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2020 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers; CD5 Antigens; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Cyclophosphamide; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.
Topics: Aging; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Y; Clone Cells; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Trisomy; Tumor Cells, Cultured; Vidarabine | 2003 |
7 trial(s) available for vidarabine and Chromosome Deletion
| Article | Year |
|---|---|
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Smith-Magenis Syndrome; Survival Rate; Vidarabine | 2015 |
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Topics: Administration, Cutaneous; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p21; DNA Mutational Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Signal Transduction; Treatment Failure; Tumor Suppressor Protein p53; Vidarabine | 2009 |
TP53 mutation and survival in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Mutation; Prognosis; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2010 |
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine | 2011 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
17 other study(ies) available for vidarabine and Chromosome Deletion
| Article | Year |
|---|---|
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine | 2020 |
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine | 2017 |
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catalytic Domain; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA Helicases; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Histones; Humans; Indoles; Ku Autoantigen; Leukemia, Lymphoid; Middle Aged; Niacinamide; Oligonucleotides; Phosphorylation; Protein Binding; Telomerase; Vidarabine | 2013 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Frameshift Mutation; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Proteins; Prognosis; Rituximab; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine | 2009 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Chronic lymphocytic leukaemia--moving towards cure?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2010 |
Risk categories and refractory CLL in the era of chemoimmunotherapy.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Forecasting; Genes, p53; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Risk Assessment; Rituximab; Terminology as Topic; Treatment Failure; Vidarabine | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Chromosome Deletion; Chromosomes, Human, Pair 17; DNA (Cytosine-5-)-Methyltransferases; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 2007 |
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Topics: Aged; Alleles; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine | 2007 |
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Kinetics of chromatid aberrations in G2 ataxia-telangiectasia cells exposed to X-rays and ara A.
Topics: Ataxia Telangiectasia; Cells, Cultured; Chromatids; Chromosome Aberrations; Chromosome Deletion; Humans; Interphase; Kinetics; Vidarabine | 1989 |
Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides.
Topics: Animals; Blotting, Southern; Cell Line; Chromosome Deletion; Cricetinae; Hypoxanthine Phosphoribosyltransferase; Mutation; RNA, Messenger; Vidarabine | 1989 |